ATE516305T1 - Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten - Google Patents
Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonistenInfo
- Publication number
- ATE516305T1 ATE516305T1 AT05707720T AT05707720T ATE516305T1 AT E516305 T1 ATE516305 T1 AT E516305T1 AT 05707720 T AT05707720 T AT 05707720T AT 05707720 T AT05707720 T AT 05707720T AT E516305 T1 ATE516305 T1 AT E516305T1
- Authority
- AT
- Austria
- Prior art keywords
- ralpha
- agonists
- antagonists
- specific
- binding site
- Prior art date
Links
- 102000003812 Interleukin-15 Human genes 0.000 title abstract 4
- 108090000172 Interleukin-15 Proteins 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 abstract 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 abstract 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000056003 human IL15 Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290542 | 2004-02-27 | ||
| PCT/EP2005/002367 WO2005085282A1 (en) | 2004-02-27 | 2005-02-10 | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516305T1 true ATE516305T1 (de) | 2011-07-15 |
Family
ID=34917212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05707720T ATE516305T1 (de) | 2004-02-27 | 2005-02-10 | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7858081B2 (de) |
| EP (1) | EP1718670B1 (de) |
| JP (3) | JP5744369B2 (de) |
| AT (1) | ATE516305T1 (de) |
| ES (1) | ES2367027T3 (de) |
| WO (1) | WO2005085282A1 (de) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5744369B2 (ja) * | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体 |
| NZ580607A (en) | 2004-05-27 | 2011-05-27 | Crucell Holland Bv | Binding molecules capable of neutralizing rabies virus and uses thereof |
| CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
| EP3263581B2 (de) | 2005-05-17 | 2025-07-09 | University of Connecticut | Zusammensetzungen und verfahren zur immunmodulation in einem organismus |
| EP1777294A1 (de) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine |
| EP2251034B1 (de) | 2005-12-02 | 2018-02-14 | Icahn School of Medicine at Mount Sinai | Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung |
| MX357691B (es) | 2006-01-13 | 2018-07-19 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas. |
| ES2642008T3 (es) | 2007-05-11 | 2017-11-14 | Altor Bioscience Corporation | Moléculas de fusión y variantes de IL-15 |
| AU2013273643C1 (en) * | 2007-05-11 | 2016-08-11 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| AU2008269032B2 (en) * | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| CU23716A1 (es) | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| WO2011031986A1 (en) | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Assays for soluble il-15 receptor alpha |
| WO2011032179A1 (en) * | 2009-09-14 | 2011-03-17 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| EP3851459B1 (de) | 2010-09-21 | 2024-05-01 | Altor BioScience, LLC | Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| EP2537933A1 (de) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine |
| EP2911684B1 (de) | 2012-10-24 | 2019-06-19 | Novartis Ag | Il-15r-alpha-formen, il-15r-alpha-formen exprimierende zellen und therapeutische verwendung von il-15r-alpha und il-15/il-15r-alpha-komplexen |
| AU2014241843B2 (en) | 2013-03-14 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| WO2014170032A1 (en) | 2013-04-19 | 2014-10-23 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| ES2698375T3 (es) * | 2013-06-27 | 2019-02-04 | Inst Nat Sante Rech Med | Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias |
| PT3030262T (pt) | 2013-08-08 | 2019-12-11 | Inst Gustave Roussy Igr | Composição farmacêutica de associação |
| CN105612175B (zh) * | 2013-08-08 | 2023-05-09 | 赛腾制药 | 基于IL-15和IL-15Rαsushi结构域的调节因子 |
| ES2904276T3 (es) | 2013-09-27 | 2022-04-04 | Massachusetts Inst Technology | Nanoestructuras de proteínas biológicamente activas sin vehículo |
| RU2689717C2 (ru) | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
| EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
| KR102762243B1 (ko) | 2014-06-30 | 2025-02-05 | 알토 바이오사이언스 엘엘씨 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| WO2016018920A1 (en) | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| AU2015333827A1 (en) * | 2014-10-14 | 2017-04-20 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| EP3064507A1 (de) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon |
| JP2019503348A (ja) * | 2015-12-21 | 2019-02-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１５組成物及びその使用 |
| EP3468581A1 (de) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| PE20240950A1 (es) | 2016-10-14 | 2024-05-06 | Xencor Inc | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) |
| EP3529263B1 (de) | 2016-10-21 | 2025-08-06 | Altor BioScience Corporation | Multimere auf il-15-basierende moleküle |
| CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2018229706A1 (en) * | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| AU2018288715A1 (en) | 2017-06-20 | 2019-12-12 | Immunitybio, Inc. | NK-92 cells and IL-15 agonist combination therapy |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| EP3678701A4 (de) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| CN112004547A (zh) * | 2018-02-26 | 2020-11-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| EP3759129A1 (de) | 2018-02-28 | 2021-01-06 | Pfizer Inc | Il-15-varianten und verwendungen davon |
| BR112020019639A2 (pt) * | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
| EP3781597A1 (de) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Gegen lag-3 gerichtete heterodimere fusionsproteine mit il-15 und il-15ra-fc-fusionsproteinen und lag-3-antigenbindungsdomänen |
| EP3781596A1 (de) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Il-15/il-15ra-heterodimere fc-fusionsproteine und verwendungen davon |
| MX2020010910A (es) | 2018-04-18 | 2021-02-09 | Xencor Inc | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. |
| KR20210003814A (ko) * | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| KR102848197B1 (ko) | 2018-06-22 | 2025-08-21 | 큐진 인크. | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
| US11634467B2 (en) | 2018-06-22 | 2023-04-25 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| BR112021006783A2 (pt) | 2018-10-12 | 2021-07-13 | Xencor, Inc. | proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer. |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| EP4019536A4 (de) | 2019-08-19 | 2023-09-06 | Nantong Yichen Biopharma. Co. Ltd. | Immunocytotin, seine herstellung und seine verwendung |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| US20210188933A1 (en) * | 2019-12-18 | 2021-06-24 | Nantcell, Inc | Methods of treating pancytopenia |
| WO2021142476A1 (en) | 2020-01-12 | 2021-07-15 | Dragonfly Therapeutics, Inc. | Single-chain polypeptides |
| CN118598977A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| EP4232068A1 (de) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma-agonist zur behandlung von nichtmelanom-hautkrebs |
| EP4232069A1 (de) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma-agonist zur behandlung von plattenepithelkarzinom |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| WO2023017191A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024170555A1 (en) | 2023-02-14 | 2024-08-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Il-15 fusion proteins with improved properties |
| WO2024216170A2 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4694916A1 (de) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Gentechnisch veränderte immunzellen zur behandlung von krebs in kombination mit il-2/il-15-rezeptor agonisten |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025222129A2 (en) * | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552303A (en) * | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6001973A (en) * | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| US6451308B1 (en) * | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| JP5744369B2 (ja) * | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体 |
-
2005
- 2005-02-10 JP JP2007500188A patent/JP5744369B2/ja not_active Expired - Fee Related
- 2005-02-10 US US10/590,734 patent/US7858081B2/en not_active Expired - Fee Related
- 2005-02-10 WO PCT/EP2005/002367 patent/WO2005085282A1/en not_active Ceased
- 2005-02-10 ES ES05707720T patent/ES2367027T3/es not_active Expired - Lifetime
- 2005-02-10 AT AT05707720T patent/ATE516305T1/de not_active IP Right Cessation
- 2005-02-10 EP EP05707720A patent/EP1718670B1/de not_active Expired - Lifetime
-
2010
- 2010-12-23 US US12/978,115 patent/US9493533B2/en not_active Expired - Fee Related
-
2012
- 2012-12-28 JP JP2012287740A patent/JP5819281B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-02 JP JP2015133396A patent/JP2015214561A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005085282A1 (en) | 2005-09-15 |
| ES2367027T3 (es) | 2011-10-27 |
| JP2007528726A (ja) | 2007-10-18 |
| US7858081B2 (en) | 2010-12-28 |
| US20110158938A1 (en) | 2011-06-30 |
| JP5819281B2 (ja) | 2015-11-24 |
| EP1718670A1 (de) | 2006-11-08 |
| JP2013081472A (ja) | 2013-05-09 |
| US9493533B2 (en) | 2016-11-15 |
| JP5744369B2 (ja) | 2015-07-08 |
| EP1718670B1 (de) | 2011-07-13 |
| US20080255039A1 (en) | 2008-10-16 |
| JP2015214561A (ja) | 2015-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516305T1 (de) | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten | |
| ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
| MY138267A (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| TNSN04001A1 (fr) | Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. | |
| LV12639A (lv) | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | |
| ATE364618T1 (de) | Antikörper gegen das muc18-antigen | |
| PT1135153E (pt) | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares | |
| MA29663B1 (fr) | Modification du facteur fviii en fonction du site | |
| EP1605936A4 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| DE60226499D1 (de) | Verwendung von antikörpern gegen das muc18-antigen | |
| EP1993560A4 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| EP1576011A4 (de) | Hemmung von il-17 produktion | |
| MX2021015651A (es) | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). | |
| BRPI0412537A (pt) | antagonista do receptor muscarìnico da acetilcolina | |
| CO5460266A1 (es) | Novedosos analogos de la somatostatina | |
| DE60236212D1 (de) | Neue isoform des gefässendothelzell wachstumshemmers (vegi) | |
| UA87122C2 (ru) | Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения | |
| ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
| ATE390148T1 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| DE60319135D1 (de) | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden | |
| ATE373718T1 (de) | 17867, eine menschliche aminopeptidase | |
| CY1108643T1 (el) | Κυτταρικη σειρα και χρησεις της | |
| EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |